Regulation of xenobiotic receptors PXR and CAR: implications in drug disposition

外源性受体 PXR 和 CAR 的调节：对药物处置的影响

• 批准号: 9889965
• 负责人: Taosheng Chen
• 金额: $ 30.01万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9889965
• 关键词: Affect; Agonist; Binding; Biological Availability; Cell physiology; Cells; Chemicals; Comprehension; Crystallization; DNA; Development; Diabetes Mellitus; Drug Sensitization; Drug resistance; Drug toxicity; Elements; Enzymes; Funding; Genes; Genetic Transcription; Genotoxic Stress; Goals; Homeostasis; Human; Human body; Malignant Neoplasms; MicroRNAs; Nuclear Receptors; Pathway interactions; Pharmaceutical Preparations; Post-Transcriptional Regulation; Post-Translational Protein Processing; Proteins; RXR; Regulation; Role; Signal Transduction; Signaling Molecule; Structure; Therapeutic; Toxic effect; Treatment Efficacy; Treatment Failure; Xenobiotics; analog; chemotherapeutic agent; constitutive androstane receptor; drug disposition; drug metabolism; genetic corepressor; genotoxicity; human disease; improved; novel; pregnane X receptor; prevent; promoter; protein protein interaction; public health relevance; receptor; receptor binding; response; tool

 DESCRIPTION (provided by applicant): We study regulation of the human pregnane X receptor (hPXR) and constitutive androstane receptor (hCAR) and their roles in drug disposition. Both hPXR and hCAR: 1) are nuclear receptors modulated by many structurally diverse chemicals, either directly via receptor binding or indirectly via signaling cross-talk; 2) transcriptionally regulate drug metabolizing enzymes and transporters to control xenobiotic disposition and endobiotic homeostasis; 3) are implicated not only in drug effects but also in the development of human diseases, such as diabetes and cancer; 4)form heterodimers with retinoid X receptor to bind the promoters of their target genes, which may be unique to a receptor or overlap; 5) are affected by coactivators and corepressors; and 6) interact similarly or differently with various regulatory partners, including chemicals, DNA elements, proteins, and microRNAs. Several key gaps remain in our overall understanding of hPXR and hCAR regulation and function. First, hPXR and hCAR not only regulate drug metabolism but also interact with other signaling molecules, regulating or being regulated by them. Despite ongoing progress, we lack a complete picture of hPXR and hCAR interactions with their regulators, and of the regulation by and regulation of these interactions. Second, a systematic effort is needed to develop chemical tools to dissect hPXR and hCAR regulation in detail. Our two long-term goals are to comprehensively examine the regulation of hPXR and hCAR and its implications for drug disposition and human diseases, and to develop chemical tools to elucidate hPXR and hCAR regulation and its potential application for preventing drug toxicity and improving bioavailability. We have advanced toward these goals by discovering mechanisms that regulate hPXR and hCAR, including protein-protein interactions, post-translational modification and post-transcriptional regulation (microRNAs), and by developing the novel hPXR antagonist SPA70, the hCAR inverse agonist CINPA1, and their analogs. We will meet 3 challenges during the funding period: (1) Illustrate how hPXR and hCAR regulate drug toxicity and resistance by examining to what extent SPA70 prevents drug toxicity and CINPA1 reduces drug resistance and determining the underlying mechanisms. (2) Define the fundamental mechanism responsible for the action of hPXR antagonists and hCAR inverse agonists by obtaining the co-crystal structures of hPXR with antagonist (SPA70) and hCAR with inverse agonist (CINPA1) and carrying out structural-functional analysis. (3) Better understand hPXR and hCAR protein-protein interaction networks and reciprocal regulatory effects, starting by examining how signaling cross-talk between genotoxic- and xenobiotic-responsive pathways reduces the effect of genotoxic stress. Together, our findings will provide not only a broader comprehension of the regulation of hPXR and hCAR and how they control the human body's response to xenobiotic s and endobiotics, but also novel modulators of hPXR and hCAR for further interrogating their broad cellular function, and as leads for therapies to prevent drug toxicity and improve drug bioavailability.

 描述（由申请人提供）：我们研究了人雄烷X受体（hPXR）和组成型雄烷受体（hCAR）的调节及其在药物处置中的作用。hPXR和hCAR：1）是由许多结构上不同的化学物质调节的核受体，直接通过受体结合或间接通过信号传导串扰; 2）转录调节药物代谢酶和转运蛋白以控制异生物质处置和内源性稳态; 3）不仅涉及药物作用，而且涉及人类疾病如糖尿病和癌症的发展; 4）与类维生素A X受体形成异二聚体以结合其靶基因的启动子，所述启动子可能是受体所独有的或重叠的; 5）受辅激活子和辅阻遏子影响;以及6）类似地相互作用或相互作用。 不同的监管伙伴，包括化学品，DNA元件，蛋白质和microRNA。在我们对hPXR和hCAR调控和功能的整体理解中仍然存在几个关键空白。首先，hPXR和hCAR不仅调节药物代谢，还与其他信号分子相互作用，调节或被调节。尽管不断取得进展，但我们缺乏hPXR和hCAR与其监管机构相互作用的完整图片，以及这些相互作用的调节和调节。其次，需要系统地努力开发化学工具来详细分析hPXR和hCAR调控。我们的两个长期目标是全面研究hPXR和hCAR的调节及其对药物处置和人类疾病的影响，并开发化学工具来阐明hPXR和hCAR调节及其在预防药物毒性和提高生物利用度方面的潜在应用。我们已经通过发现调节hPXR和hCAR的机制，包括蛋白质-蛋白质相互作用，翻译后修饰和转录后调节（microRNA），并通过开发新的hPXR拮抗剂SPA 70，hCAR反向激动剂CINPA 1及其类似物，朝着这些目标前进。在资助期间，我们将面临3个挑战：（1）通过检查SPA 70在多大程度上防止药物毒性和CINPA 1减少耐药性并确定潜在机制，阐明hPXR和hCAR如何调节药物毒性和耐药性。(2)通过获得hPXR与拮抗剂（SPA 70）和hCAR与反向激动剂（CINPA 1）的共晶结构并进行结构-功能分析，确定hPXR拮抗剂和hCAR反向激动剂作用的基本机制。(3)更好地了解hPXR和hCAR蛋白质-蛋白质相互作用网络和相互调节效应，首先研究遗传毒性和外源性反应途径之间的信号串扰如何降低遗传毒性应激的影响。总之，我们的研究结果不仅将提供对hPXR和hCAR的调节以及它们如何控制人体对外源性物质和内生物质的反应的更广泛的理解，而且还将提供hPXR和hCAR的新型调节剂，以进一步询问其广泛的细胞功能，并作为预防药物毒性和提高药物生物利用度的治疗方法的先导。